keyword
MENU ▼
Read by QxMD icon Read
search

Her2 positive, hormone positive

keyword
https://www.readbyqxmd.com/read/29783652/pituitary-gonadal-thyroid-hormones-and-endocrine-disruptors-in-pre-and-postmenopausal-nigerian-women-with-er-pr-and-her-2-positive-and-negative-breast-cancers
#1
Olulope Ajayi, Mabel Charles-Davies, John Anetor, Adeyinka Ademola
Breast cancer is broadly sub-divided into hormone responsive and non-hormone responsive subtypes. Estradiol has been associated with hormone responsive breast cancers. There is, however, a paucity of information on the role of sex hormones, gonadotropins, and thyroid hormone in non-hormone responsive breast cancer. This study aimed to determine differences in the serum levels of sex hormones, gonadotropins, thyroid hormones, and endocrine disruptors (lead, cadmium, and arsenic) in Nigerian women with hormone responsive and non-hormone responsive breast cancers...
May 18, 2018: Medical Sciences: Open Access Journal
https://www.readbyqxmd.com/read/29780255/predicting-initial-margin-status-in-breast-cancer-patients-during-breast-conserving-surgery
#2
Zihao Pan, Liling Zhu, Qian Li, Jianguo Lai, Jingwen Peng, Fengxi Su, Shunrong Li, Kai Chen
Background: We sought to develop and validate a model for prediction of initial margin status during breast-conserving surgery (BCS). Methods: We included eligible breast cancer patients receiving BCS in Sun Yat-sen Memorial Hospital from January 2003 to December 2014. All patients received intraoperative frozen-section analysis for initial margin assessment. We used univariate and multivariate logistic regression analyses to screen for predictors. A nomogram was developed in the training cohort (n=1,193) from the south branch of the hospital and externally validated in the validation cohort (n=499) from the north branch...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29779938/expression-of-truncated-her2-and-its-prognostic-value-in-her2-positive-breast-cancer-patients
#3
Alaa Mohamed Maria, Mohamed El-Shebiney, Ayman Mohamed El-Saka, Yomna Zamzam
PURPOSE: The purpose of this work was to assess the truncated form of human epidermal growth factor receptor 2 (HER2) such as p95-HER2 expression in HER2-positive breast cancer (BC) patients who developed metastatic disease after adjuvant treatment with a trastuzumab-containing regimen. PATIENTS AND METHODS: Thirty-two histologically diagnosed HER2-positive BC patients who developed distant failure after treatment with trastuzumab-based chemotherapy (CT) regimen as an adjuvant therapy were included in the study...
May 17, 2018: Journal of the Egyptian National Cancer Institute
https://www.readbyqxmd.com/read/29778787/efficacy-of-palbociclib-combinations-in-hormone-receptor-positive-metastatic-breast-cancer-patients-after-prior-everolimus-treatment
#4
Ajay Dhakal, Christina M Matthews, Ellis Glenn Levine, Kilian Elizabeth Salerno, Fan Zhang, Kazuaki Takabe, Amy P Early, Stephen B Edge, Tracy O'Connor, Thaer Khoury, Jessica S Young, Mateusz Opyrchal
PURPOSE: Outcome data on hormone receptor positive (HR+ ), human epidermal growth factor receptor 2 (HER2) nonamplified (HER2- ) metastatic breast cancer (MBC) treated with palbociclib after treatment with everolimus are lacking. The PALOMA-3 trial, showing benefit of palbociclib plus fulvestrant compared to fulvestrant alone in HR+ HER2- MBC after progression while receiving endocrine therapy excluded women previously treated with everolimus. The objective of this study was to examine outcomes of HR+ HER2- MBC with prior exposure to everolimus while receiving palbociclib-based therapy...
April 28, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29772837/conventional-pathology-versus-gene-signatures-for-assessing-luminal-a-and-b-type-breast-cancers-results-of-a-prospective-cohort-study
#5
Julia E C van Steenhoven, Anne Kuijer, Paul J van Diest, Joost M van Gorp, Marieke Straver, Sjoerd G Elias, Jelle Wesseling, Emiel Rutgers, Johanna N H Timmer-Bonte, Peter Nieboer, Tineke J Smilde, Alex Imholz, Charlotte F J M Blanken, Sabine Siesling, Thijs van Dalen
In this study, in estrogen receptor positive (ER+) early stage breast cancer patients who were considered candidates for 70-gene signature (70-GS, "MammaPrint") use, we compared molecular subtyping (MS) based on the previously validated 80-gene signature (80-GS, "BluePrint") versus surrogate pathological subtyping (PS). Between 1 January 2013 and 31 December 2015, 595 clinical intermediate risk ER+ early stage breast cancer patients were enrolled. Hormone receptor (HR) and HER2 receptor status were determined by conventional pathology using immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH)...
May 17, 2018: Genes
https://www.readbyqxmd.com/read/29769179/rna-profiles-of-circulating-tumor-cells-and-extracellular-vesicles-for-therapy-stratification-of-metastatic-breast-cancer-patients
#6
Corinna Keup, Pawel Mach, Bahriye Aktas, Mitra Tewes, Hans-Christian Kolberg, Siegfried Hauch, Markus Sprenger-Haussels, Rainer Kimmig, Sabine Kasimir-Bauer
BACKGROUND: Liquid biopsies are discussed to provide surrogate markers for therapy stratification and monitoring. We compared messenger RNA (mRNA) profiles of circulating tumor cells (CTCs) and extracellular vesicles (EVs) in patients with metastatic breast cancer (MBC) to estimate their utility in therapy management. METHODS: Blood was collected from 35 hormone receptor-positive/HER2-negative patients with MBC at the time of disease progression and at 2 consecutive staging time points...
May 16, 2018: Clinical Chemistry
https://www.readbyqxmd.com/read/29768351/the-cdk4-6-inhibitor-in-hr-positive-advanced-breast-cancer-a-systematic-review-and-meta-analysis
#7
Wu Ding, Zhian Li, Caiyun Wang, GuoDong Ruan, LuPing Chen, Chuanjian Tu
BACKGROUND: Recently, several high-quality clinical randomized controlled trials (RCTs) have identified that cyclin-dependent kinases (CDKs) 4/6 inhibitors obtained a great safety and efficacy, which can be consequently applied as a combination therapy with letrozole or fulvestrant for women who had advanced breast cancer and progressed while receiving endocrine therapy. In this systemic review, we performed a meta-analysis to explore whether CDK4/6 inhibitors had a significantly benefit to treating hormone receptor-positive (HR-positive)/human epidermal growth factor receptor 2 negative (HER2-negative) advanced breast cancer...
May 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29766456/prognostic-role-for-the-derived-neutrophil-to-lymphocyte-ratio-in-early-breast-cancer-a-geicam-9906-substudy
#8
A J Templeton, Á Rodríguez-Lescure, A Ruíz, E Alba, L Calvo, M Ruíz-Borrego, A Santaballa, C A Rodríguez, C Crespo, M Ramos, J M Gracia-Marco, A Lluch, I Álvarez, M I Casas, M Sánchez-Aragó, R Caballero, E Carrasco, E Amir, M Martin, A Ocaña
PURPOSE: Elevated markers of host inflammation, a hallmark of cancer, have been associated with worse outcomes in several solid tumors. Here, we explore the prognostic role of the derived neutrophil-to-lymphocyte ratio (dNLR), across different tumor subtypes, in patients with early breast cancer. PATIENTS AND METHODS: This was a retrospective analysis of 1246 patients with lymph node-positive, operable early breast cancer enrolled in the GEICAM/9906 trial, a multicenter randomized phase 3 study evaluating adjuvant chemotherapy...
May 15, 2018: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29765249/is-progression-free-survival-a-more-relevant-endpoint-than-overall-survival-in-first-line-hr-her2-metastatic-breast-cancer
#9
Anna Forsythe, David Chandiwana, Janina Barth, Marroon Thabane, Johan Baeck, Anastasiya Shor, Gabriel Tremblay
Background: Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), metastatic breast cancer (MBC) accounts for 73% of all MBCs. Endocrine therapy (ET) is the basis of first-line (1L) therapy for patients with HR+/HER2- MBC. Novel therapies have demonstrated improvements in progression-free survival (PFS) compared to ET. The clinical relevance of PFS is being debated, as there is no proven direct correlation with overall survival (OS) benefit to date...
2018: Cancer Management and Research
https://www.readbyqxmd.com/read/29765247/progression-free-survival-time-to-progression-as-a-potential-surrogate-for-overall-survival-in-hr-her2-metastatic-breast-cancer
#10
Anna Forsythe, David Chandiwana, Janina Barth, Marroon Thabane, Johan Baeck, Gabriel Tremblay
Background: Several recent randomized controlled trials (RCTs) in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) have demonstrated significant improvements in progression-free survival (PFS); however, few have reported improvement in overall survival (OS). The surrogacy of PFS or time to progression (TTP) for OS has not been formally investigated in HR+, HER2- MBC. Methods: A systematic literature review of RCTs in HR+, HER2- MBC was conducted to identify studies that reported both median PFS/TTP and OS...
2018: Breast Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/29763896/evaluation-of-the-her2-and-hormone-receptor-status-in-metastatic-breast-cancer-using-cell-blocks-a-multi-institutional-study
#11
Rieko Nishimura, Yuya Murata, Kiyoshi Mori, Katsushige Yamashiro, Kazuya Kuraoka, Shu Ichihara, Kenichi Taguchi, Hiroyoshi Suzuki, Masahiro Ito, Natsumi Yamashita
OBJECTIVE: We explore the problems associated with the cell block (CB) method for receptor analysis in breast cancer metastases and propose a method for reporting the results. STUDY DESIGN: Nine institutions used the CB method for the analysis of hormone receptors (HRs) and HER2 (human epidermal growth factor receptor 2) protein in cytological specimens of breast cancer metastases in routine practice. The stained slides were independently evaluated by 8 pathologists...
May 15, 2018: Acta Cytologica
https://www.readbyqxmd.com/read/29763779/clinical-implications-of-the-non-luminal-intrinsic-subtypes-in-hormone-receptor-positive-breast-cancer
#12
REVIEW
Juan Miguel Cejalvo, Tomás Pascual, Aranzazu Fernández-Martínez, Fara Brasó-Maristany, Roger R Gomis, Charles M Perou, Montserrat Muñoz, Aleix Prat
Gene expression profiling has had a considerable impact on our understanding ofbreastcancer biology. Duringthelast decade, 4 intrinsic molecular subtypes of breast cancer (Luminal A, Luminal B, HER2-enriched [HER2-E] and Basal-like) have been identified and intensively studied. In this article, we review and discuss the clinical implications of the 2 non-luminal subtypes (i.e. HER2-E and Basal-like) identified within hormone receptor (HR)-positive disease. After reviewing 32 studies for a total of 13,091 samples, ∼8% and ∼ 15% of early and metastatic HR+/HER2-negative breast cancer, respectively, were found to be non-luminal...
May 7, 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29745076/ten-years-of-using-adjuvant-trastuzumab-in-breast-cancer-in-serbia-single-institution-experience
#13
Ana Cvetanovic, Sladjana Filipovic, Nikola Zivkovic, Lazar Popovic, Milos Kostic, Miodrag Djordjevic, Aleksandar Karanikolic, Dane Krtinic
PURPOSE: The purpose of this study was to determinate disease-free interval (DFI) and overall survival (OS) in HER2-positive breast cancer patients who received adjuvant trastuzumab at the University Clinic of Nis, Serbia, and to investigate the influence of clinicopathological and biological characteristics of the tumor on prognosis. The second aim was to determinate the most frequent cause for the treatment discontinuation, recurrence rate, as well as the site of most common localization of the first recurrence of disease...
March 2018: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29744672/efficacy-and-safety-of-neoadjuvant-treatment-with-bevacizumab-liposomal-doxorubicin-cyclophosphamide-and-paclitaxel-combination-in-locally-regionally-advanced-her2-negative-grade-iii-at-premenopausal-status-breast-cancer-a-phase-ii-study
#14
Ekaterini C Tampaki, Athanasios Tampakis, Constantinos E Alifieris, Dimitrios Krikelis, Anastasia Pazaiti, Michalis Kontos, Dimitrios T Trafalis
BACKGROUND: In the era of personalized therapy, targeted treatment in specific patient populations is mandated. OBJECTIVE: We evaluated the efficacy and safety of neoadjuvant treatment on locally advanced breast cancer (LABC) with a monoclonal agent against vascular endothelial growth factor (VEGF), bevacizumab plus chemotherapy combination of liposomal doxorubicin, cyclophosphamide and paclitaxel (PLAC-B). METHODS: Patients enrolled were at premenopausal status and characterized by human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor positive (estrogen receptor/progesterone receptor-positive [ER/PR+]) or triple-negative (TNBC), LABC (T > 3 cm), with high-grade ductal carcinoma...
May 9, 2018: Clinical Drug Investigation
https://www.readbyqxmd.com/read/29743141/chemotherapy-patient-with-stevens-johnson-syndrome-presents-to-the-emergency-department-a-case-report
#15
Stephanie Widmer, Michele Grossman
BACKGROUND: Stevens-Johnson syndrome (SJS) is part of a continuum of severe mucocutaneous reactions, commonly thought to be triggered by certain medications. The syndrome itself is characterized by diffuse necrosis and detachment of the epidermis. CASE REPORT: This case report discusses a patient who presented to the Emergency Department with signs and symptoms of Stevens-Johnson syndrome four days after chemotherapy administration of ribociclib (Kisqali®). Ribociclib is a newly approved, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor indicated for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer...
April 11, 2018: American Journal of Emergency Medicine
https://www.readbyqxmd.com/read/29739815/impact-of-hormone-receptor-status-on-the-efficacy-of-her2-targeted-treatment
#16
Bin Zhao, Hong Zhao, Jiaxin Zhao
The introduction of human epidermal growth factor receptor 2 (HER2)-targeted drugs into routine clinical practice has a dramatic effect on the outlook for patients with HER2-positive breast cancer (BC). However, the association between efficacy of HER2-targeted therapy and hormone receptor (HR) status is still unclear. Here we conducted a meta-analysis of randomized controlled trials (RCTs) to address this issue in both neoadjuvant and adjuvant settings. PubMed and EMBASE were searched from inception to October 2017 for studies involving trastuzumab, lapatinib, pertuzumab, trastuzumab emtansine and neratinib...
June 2018: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29731982/gene-specific-methylation-profiles-in-brca-mutation-positive-and-brca-mutation-negative-male-breast-cancers
#17
Piera Rizzolo, Valentina Silvestri, Virginia Valentini, Veronica Zelli, Ines Zanna, Giovanna Masala, Simonetta Bianchi, Domenico Palli, Laura Ottini
Male breast cancer (MBC) is a rare disease. Due to its rarity, MBC research and clinical approach are mostly based upon data derived from female breast cancer (FBC). Increasing evidence indicate that on molecular level MBC may be an heterogeneous disease different from FBC. In order to investigate whether epigenetic signatures could define molecular subgroups of MBCs, we performed promoter methylation analysis of genes involved in signal transduction and hormone signalling in BRCA1/2 mutation-positive and -negative MBCs...
April 13, 2018: Oncotarget
https://www.readbyqxmd.com/read/29725889/use-of-cyclin-dependent-kinase-cdk-4-6-inhibitors-for-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-metastatic-breast-cancer-a-roundtable-discussion-by-the-breast-cancer-therapy-expert-group-bcteg
#18
REVIEW
Jame Abraham, Robert Coleman, Anthony Elias, Frankie Ann Holmes, Kevin Kalinsky, Muaiad Kittaneh, Elyse Lower, Reshma Mahtani, E Terry Mamounas, Mark Pegram, Charles Vogel
PURPOSE: To provide an overview of clinical data supporting the use of cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitors in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), metastatic breast cancer (mBC), from the perspective of the practicing oncologist community. METHODS: A recent roundtable discussion was convened by The Breast Cancer Therapy Expert Group (BCTEG) to review existing data on this topic and its impact on their current practice...
May 4, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29721483/practical-consensus-recommendations-regarding-the-management-of-her2-neu-positive-metastatic-breast-cancer
#19
M Basade, M Singhal, A K Rathi, M Nandi, S Minhas, C Goswami, S Shinde, P M Parikh, S Aggarwal
Metastatic breast cancer (MBC) is cancer that has spread from the breast to another part of the body or has come back in another distant location. Treatment options for MBC depend on several factors, including where the cancer has spread, the patient's overall health, and the levels of hormone receptors and HER2 in the tumour. Over-expression of HER2 is generally considered to be a negative prognostic feature because it accompanies an increase in breast cancer mortality. However, the development of agents that specifically target HER2 has improved the management of patients with these tumours...
April 2018: South Asian Journal of Cancer
https://www.readbyqxmd.com/read/29721472/practical-consensus-recommendations-on-management-of-hr-ve-early-breast-cancer-with-specific-reference-to-genomic-profiling
#20
S Aggarwal, A Vaid, A Ramesh, Purvish M Parikh, S Purohit, B Avasthi, S Gupta, S Ranjan, V Kaushal, S Salim, R Singh, S Minhas, D Doval
Breast cancer is a heterogeneous disease and patients are managed clinically based on ER, PR, HER2 expression, and key risk factors. The use of gene expression assays for early stage disease is already common practice. These tests have found a place in risk stratifying the heterogeneous group of stage I-II breast cancers for recurrence, for predicting chemotherapy response, and for predicting breast cancer-related mortality. Most guidelines for hormone receptor (HR)-positive early breast cancer recommend addition of adjuvant chemotherapy for most women, leading to overtreatment, which causes considerable morbidity and cost...
April 2018: South Asian Journal of Cancer
keyword
keyword
21972
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"